Abstract

Broad-spectrum host-directed antivirals are urgently needed, as virus-targeted drugs often suffer from narrow specificity and rapid resistance. Here, we reported that Betrixaban (BT), an FDA-approved oral Factor Xa inhibitor, induced a robust antiviral state through dual innate immune pathways. Mechanistically, we identified BT as the first small molecule to directly bind and activate the DNA sensor cGAS to induce cGAMP production. Concurrently, BT inhibited histone deacetylases (HDACs), leading to chromatin de-repression of endogenous retroviruses (ERVs) and production of immunostimulatory double-stranded RNA (dsRNA) that engaged RIG-I/MDA5. These combined signal cascades triggered strong type I interferon responses and conferred broad-spectrum antiviral protection against RNA and DNA viruses in vitro and in vivo. These findings unveil a unique host-directed antiviral strategy wherein a small-molecule drug engages dual nucleic acid-sensing pathway, and suggest repurposing BT as an orally broad-spectrum antiviral. In this study, Betrixaban (BT) was shown to activate innate antiviral immunity by dual mechanism: direct cGAS sensitization and HDACi-driven ERV/RIG-I/MDA5 signaling, providing broad protection in cells and mice. In this study, Betrixaban (BT) was shown to activate innate antiviral immunity by dual mechanism: direct cGAS sensitization and HDACi-driven ERV/RIG-I/MDA5 signaling, providing broad protection in cells and mice.